4142 Stock Overview
Adimmune Corporation manufactures and sells human vaccines in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4142 from our risk checks.
Adimmune Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$28.50 |
| 52 Week High | NT$41.15 |
| 52 Week Low | NT$25.00 |
| Beta | 0.45 |
| 1 Month Change | 6.74% |
| 3 Month Change | -8.21% |
| 1 Year Change | -28.66% |
| 3 Year Change | -46.33% |
| 5 Year Change | 39.02% |
| Change since IPO | -59.29% |
Recent News & Updates
Shareholder Returns
| 4142 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 7.1% | -3.4% | -2.1% |
| 1Y | -28.7% | -25.4% | 27.5% |
Return vs Industry: 4142 underperformed the TW Biotechs industry which returned -26.4% over the past year.
Return vs Market: 4142 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 4142 volatility | |
|---|---|
| 4142 Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4142 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4142's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | n/a | Steve Chan | www.adimmune.com.tw |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.
Adimmune Corporation Fundamentals Summary
| 4142 fundamental statistics | |
|---|---|
| Market cap | NT$12.01b |
| Earnings (TTM) | -NT$639.89m |
| Revenue (TTM) | NT$1.79b |
6.7x
P/S Ratio-18.8x
P/E RatioIs 4142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4142 income statement (TTM) | |
|---|---|
| Revenue | NT$1.79b |
| Cost of Revenue | NT$1.37b |
| Gross Profit | NT$410.94m |
| Other Expenses | NT$1.05b |
| Earnings | -NT$639.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 23.02% |
| Net Profit Margin | -35.85% |
| Debt/Equity Ratio | 53.3% |
How did 4142 perform over the long term?
See historical performance and comparison